Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138133 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
A Phase 3 study of Lupus Nephritis, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 359
- Enrollment target
- 20
- Study locations
NCT05138133: Active Phase 3 study of Lupus Nephritis, sponsored by AstraZeneca.
NCT05138133 is a Phase 3 study of Lupus Nephritis that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 359 participants, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05138133, a Phase 3 study of Lupus Nephritis, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 359 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Primary Outcome
CRR is defined as: * UPCR ≤ 0.5 mg/mg * eGFR ≥ 60 mL/min/1.73 m2 or no decrease from baseline of ≥ 20%
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Anifrolumab
Study Locations (20)
Texas
- Research Site - Colleyville
- Research Site - Edinburg
- Research Site - El Paso
- Research Site - Houston
Other
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - La Plata
- Research Site - Rosario
California
- Research Site - La Palma
- Research Site - Los Angeles
- Research Site - Upland
New York
- Research Site - Manhasset
- Research Site - New York
Arizona
- Research Site - Glendale
Florida
- Research Site - Plantation
Georgia
- Research Site - Atlanta
Kentucky
- Research Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2028-12-05 |
| Phase | Phase 3 |
What the registry record for NCT05138133 still lists
NCT05138133 is an interventional study that assigns participants to a tested intervention. The registered 359 participants enrollment target is mid-sized for trials with a published cap, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05138133 names 20 study sites across 11 states, led by Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT05138133 about?
NCT05138133 is a clinical study titled "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis". The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
What is the current status of trial NCT05138133?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2022-02-15. Estimated completion is 2028-12-05.
What conditions does trial NCT05138133 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT05138133?
The interventions under investigation include: Placebo (DRUG), Anifrolumab (DRUG).
Who is sponsoring clinical trial NCT05138133?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05138133 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05138133's enrollment target sits among peer trials
359 5th of 30 higher than 26 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
COMPLETED · Phase 3
-
Aurinia Renal Response in Active Lupus With Voclosporin
COMPLETED · Phase 3
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05118789 · 359 participants · Phase 1
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI